tradingkey.logo
tradingkey.logo
Search

Evaxion Biotech A/S

EVAX
Add to Watchlist
3.200USD
+0.100+3.23%
Close 07/01, 16:00ETQuotes delayed by 15 min
26.69MMarket Cap
LossP/E TTM

TradingKey Stock Score of Evaxion Biotech A/S

Currency: USD Updated: 2026-07-01

Key Insights

Evaxion Biotech A/S's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 206 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.25.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Evaxion Biotech A/S's Score

Industry at a Glance

Industry Ranking
206 / 387
Overall Ranking
378 / 4564
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Evaxion Biotech A/S Highlights

StrengthsRisks
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 10212.33% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.53M.
Undervalued
The company’s latest PE is -15.38, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 323.61K shares, increasing 1.65% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.

Analyst Rating

Based on 4 analysts
Buy
Current Rating
11.250
Target Price
+262.90%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Evaxion Biotech A/S?

The TradingKey Stock Score provides a comprehensive assessment of Evaxion Biotech A/S based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Evaxion Biotech A/S’s performance and outlook.

How do we generate the financial health score of Evaxion Biotech A/S?

To generate the financial health score of Evaxion Biotech A/S, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Evaxion Biotech A/S's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Evaxion Biotech A/S.

How do we generate the company valuation score of Evaxion Biotech A/S?

To generate the company valuation score of Evaxion Biotech A/S, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Evaxion Biotech A/S’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Evaxion Biotech A/S’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Evaxion Biotech A/S.

How do we generate the earnings forecast score of Evaxion Biotech A/S?

To calculate the earnings forecast score of Evaxion Biotech A/S, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Evaxion Biotech A/S’s future.

How do we generate the price momentum score of Evaxion Biotech A/S?

When generating the price momentum score for Evaxion Biotech A/S, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Evaxion Biotech A/S’s prices. A higher score indicates a more stable short-term price trend for Evaxion Biotech A/S.

How do we generate the institutional confidence score of Evaxion Biotech A/S?

To generate the institutional confidence score of Evaxion Biotech A/S, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Evaxion Biotech A/S’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Evaxion Biotech A/S.

How do we generate the risk management score of Evaxion Biotech A/S?

To assess the risk management score of Evaxion Biotech A/S, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Evaxion Biotech A/S’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Evaxion Biotech A/S.